Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review.
10.1038/s41368-019-0068-8
- Author:
Ran CHENG
1
;
Zhiwu WU
1
;
Mingming LI
1
;
Meiying SHAO
2
;
Tao HU
3
Author Information
1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu, China.
2. West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
3. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & West China Hospital of Stomatology, Sichuan University, Chengdu, China. hutao@scu.edu.cn.
- Publication Type:Journal Article
- From:
International Journal of Oral Science
2020;12(1):2-2
- CountryChina
- Language:English
-
Abstract:
Interleukin(IL)-1β, a pro-inflammatory cytokine, was elevated and participates in periodontitis. Not only the link between IL-1β and periodontitis was proved by clinical evidence, but also the increased IL-1β triggers a series of inflammatory reactions and promotes bone resorption. Currently, IL-1β blockage has been therapeutic strategies for autoimmune and autoinflammatory diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, gout and type II diabetes mellitus. It is speculated that IL-1β be a potential therapeutic target for periodontitis. The review focuses on the production, mechanism, present treatments and future potential strategies for IL-1β in periodontitis.
